Prognostic value of tumor deposits and positive lymph node ratio in stage III colorectal cancer: a retrospective cohort study

被引:0
作者
Liu, Lei [1 ,6 ]
Ji, Jie [7 ]
Ge, Xianxiu [1 ]
Ji, Zuhong [1 ]
Li, Jiacong [5 ]
Wu, Jie [1 ]
Zhu, Juntao [1 ]
Yao, Jianan [1 ]
Zhu, Fangyu [2 ]
Mao, Boneng [6 ]
Cao, Zhihong [6 ]
Zhou, Jinyi [2 ]
Miao, Lin [1 ]
Ji, Guozhong [1 ]
Hang, Dong [3 ,4 ,5 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 2, Med Ctr Digest Dis, 121 Jiangjiayuan Rd, Nanjing 210046, Peoples R China
[2] Nanjing Med Univ, Jiangsu Prov Ctr Dis Control & Prevent, Dept Noncommunicable Chron Dis Control, Nanjing, Peoples R China
[3] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatmen, Nanjing, Peoples R China
[4] Nanjing Med Univ, China Int Cooperat Ctr Environm & Human Hlth, Gusu Sch, Nanjing, Peoples R China
[5] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol, 101 Longmian Ave, Nanjing 211166, Peoples R China
[6] Jiangsu Univ, Affiliated Yixing Hosp, Yixing, Peoples R China
[7] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
colorectal cancer; laterality; lymph node ratio; prognosis; stage III; tumor deposits; COLON-CANCER; PHASE-III; SURVIVAL; OXALIPLATIN; METASTASES; FLUOROURACIL; CHEMOTHERAPY; ASSOCIATION; LEUCOVORIN; INDICATOR;
D O I
10.1097/JS9.0000000000001295
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: In colorectal cancer (CRC), tumor deposits (TD) have been used to guide the N staging only in node-negative patients. It remains unknown about the prognostic value of TD in combination with positive lymph node ratio (LNR) in stage III CRC. Patients and methods: The authors analyzed data from 31 139 eligible patients diagnosed with stage III CRC, including 30 230 from the Surveillance, Epidemiology, and End Results (SEER) database as a training set and 909 from two Chinese hospitals as a validation set. The associations of TD and LNR with cancer-specific survival (CSS) and overall survival (OS) were evaluated using the Kaplan-Meier method and Cox regression models. Results: Both TD-positive and high LNR (value >= 0.4) were associated with worse CSS in the training [multivariable hazard ratio (HR), 1.50; 95% CI: 1.43-1.58 and HR, 1.74; 95% CI: 1.62-1.86, respectively] and validation sets (HR, 1.90; 95% CI: 1.41-2.54 and HR, 2.01; 95% CI: 1.29-3.15, respectively). Compared to patients with TD-negative and low LNR (value<0.4), those with TD-positive and high LNR had a 4.09-fold risk of CRC-specific death in the training set (HR, 4.09; 95% CI: 3.54-4.72) and 4.60-fold risk in the validation set (HR, 4.60; 95% CI: 2.88-7.35). Patients with TD-positive/H-LNR CRC on the right side had the worst prognosis (P<0.001). The combined variable of TD and LNR contributed the most to CSS prediction in the training (24.26%) and validation (32.31%) sets. A nomogram including TD and LNR showed satisfactory discriminative ability, and calibration curves indicated favorable consistency in both the training and validation sets. Conclusions: TD and LNR represent independent prognostic predictors for stage III CRC. A combination of TD and LNR could be used to identify those at high-risk of CRC deaths.
引用
收藏
页码:3470 / 3479
页数:10
相关论文
共 29 条
  • [1] Association of primary tumor lymph node ratio with burden of liver metastases and survival in stage IV colorectal cancer
    Ahmad, Ali
    Reha, Jeffrey
    Saied, Abdul
    Espat, N. Joseph
    Somasundar, Ponnandai
    Katz, Steven C.
    [J]. HEPATOBILIARY SURGERY AND NUTRITION, 2017, 6 (03) : 154 - 161
  • [2] Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial
    Alberts, Steven R.
    Sargent, Daniel J.
    Nair, Suresh
    Mahoney, Michelle R.
    Mooney, Margaret
    Thibodeau, Stephen N.
    Smyrk, Thomas C.
    Sinicrope, Frank A.
    Chan, Emily
    Gill, Sharlene
    Kahlenberg, Morton S.
    Shields, Anthony F.
    Quesenberry, James T.
    Webb, Thomas A.
    Farr, Gist H., Jr.
    Pockaj, Barbara A.
    Grothey, Axel
    Goldberg, Richard M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (13): : 1383 - 1393
  • [3] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Andre, T
    Boni, C
    Mounedji-Boudiaf, L
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Zaninelli, M
    Clingan, P
    Bridgewater, J
    Tabah-Fisch, I
    de Gramont, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
  • [4] Brierley JD., 2017, TNM CLASSIFICATION M
  • [5] X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Camp, RL
    Dolled-Filhart, M
    Rimm, DL
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7252 - 7259
  • [6] KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013
    Charlton, Mary E.
    Kahl, Amanda R.
    Greenbaum, Alissa A.
    Karlitz, Jordan J.
    Lin, Chi
    Lynch, Charles F.
    Chen, Vivien W.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (12): : 1484 - 1493
  • [7] Lymph Node Ratio as a Quality and Prognostic Indicator in Stage III Colon Cancer
    Chen, Steven L.
    Steele, Scott R.
    Eberhardt, John
    Zhu, Kangmin
    Bilchik, Anton
    Stojadinovic, Alexander
    [J]. ANNALS OF SURGERY, 2011, 253 (01) : 82 - 87
  • [8] Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)
    Cohen, R.
    Shi, Q.
    Meyers, J.
    Jin, Z.
    Svrcek, M.
    Fuchs, C.
    Couture, F.
    Kuebler, P.
    Ciombor, K. K.
    Bendell, J.
    De Jesus-Acosta, A.
    Kumar, P.
    Lewis, D.
    Tan, B.
    Bertagnolli, M. M.
    Philip, P.
    Blanke, C.
    O'Reilly, E. M.
    Shields, A.
    Meyerhardt, J. A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (10) : 1267 - 1275
  • [9] Colorectal cancer
    Dekker, Evelien
    Tanis, Pieter J.
    Vleugels, Jasper L. A.
    Kasi, Pashtoon M.
    Wallace, Michael B.
    [J]. LANCET, 2019, 394 (10207) : 1467 - 1480
  • [10] A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification
    Delattre, Jean-Francois
    Erdogan, Ayse Selcen Oguz
    Cohen, Romain
    Shi, Qian
    Emile, Jean-Francois
    Taieb, Julien
    Tabernero, Josep
    Andre, Thierry
    Meyerhardt, Jeffrey A.
    Nagtegaal, Iris D.
    Svrcek, Magali
    [J]. CANCER TREATMENT REVIEWS, 2022, 103